IL20RA and breast carcinoma: IL20RA promoted stem cell characteristics and tumor initiation ability of breast cancer cells through JAK1–STAT3–SOX2 signaling pathway, resulting in increased expression of PD-L1 and reduced recruitment of lymphocytes, including CD8 T cells and NK cells, so as to form a tumor-favorable immune microenvironment (11).